Cell therapy developer Green Cross Cell
and biotechnology firm ToolGen on Aug. 22 signed a memorandum of understanding on collaborating in developing immune therapy for cancer.
The two companies plan to apply ToolGen’s DNA scissor technology to Green Cross Cell’s anti-cancer immune therapy.
The companies hope to amplify T-cells’ ability to attack cancer cells.
By Choi He-suk (firstname.lastname@example.org